Search

Purpose: Tumor volume has been thought to be an important predictive factor for significant prostate cancer. We assessed the impact of the tumor volume (TV) and the tumor percentage (TP) of radical prostatectomy specimens on the pathological variables and the oncological outcome. Materials and Methods: The tumor percentage and tumor volume were calculated for 525 cases by a single pathologist who determined the volume based on the surface area of the slides involved by tumor of the prostate. Univariate and multivariate logistic regression analyses were used to characterize the association of TP categories (＜5%, 5-10%, 11-20% and ＞20%) and TV (＜1.8cc, 1.8-3.7cc, 3.8-7.5cc, ＞7.5cc) with the clinicopathological variables. Biochemical recurrence (BCR) was estimated using Kaplan-Meier analysis and Cox’s hazard regression model. Results: The mean prostate cancer volume was 6.5±8.5cc (median: 3.8, range: 0.04-73.8) and the mean percent tumor composition was 0.17±0.19

Data was collected from 525 patients who un-derwent radical prostatectomy for clinically localized prostate cancer from 2003 to 2007. We evaluated the potential associations of multifocality with various clinical and pathologic factors. The ability to predict extra-capsular extension (ECE) was tested by logistic regression models, whereas bioche-mical recurrence (BCR) was assessed via Kaplan-Meier analyses and Cox-hazard regression models. The BCR was defined as a level of serum prostate-specific antigen (PSA) of 0.2ng/ml or greater on consecutive evaluations.

Results: In total, 84 (67.7%) and 40 (32.3%) of patients had final GS of 3+4 and 4+3, respectively. A final GS of 4+3 was associated with a higher pre-biopsy level of prostate-specific antigen (p

Purpose: Metabolic syndrome, a concurrence of disturbed glucose and insulin metabolism, overweight, abdominal fat distribution, dyslipidemia, and hypertension, has been reported to have some association with prostate cancer. Here, we assessed the relationship between metabolic syndrome and prostate cancer. Materials and Methods: We assessed a total of 261 men who underwent radical retropubic prostatectomy between January 2004 and May 2005. The patients were stratified into two groups, with metabolic syndrome (n=75) or without (n=186). Metabolic syndrome was defined by the criteria of National Cholesterol Education Program Adult Treatment Panel III. We compared the clinical and pathologic features of specimens between the groups. Results: There was no significant difference between the two groups in terms of mean age, serum prostate specific antigen level, prostate size, Gleason score, and pathologic stage. The tumor volume of prostate cancer was significantly higher in the metabolic syndrome group (6.6±5.5cc vs 5.0±4.5cc, p=0.010). No significant differences were observed in extracapsular extension, seminal vesicle invasion, bladder neck invasion, angiolymphatic invasion, perineural invasion, and multicentricity of cancer between the two groups. As the component of metabolic syndrome increased, the tumor volume was also found to increase (p-value=0.025). Conclusions: The data from our study support that metabolic syndrome is closely associated with the development and progression of prostate cancer. (Korean J Urol 2007;48:585-591) 󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏󰠏

Ji Hyeong Yu, Jeong Woo Lee, In Ho Chang, Jun Hyun Han, Byoung Kyu Han, Seong-Jin Jeong, Sung Kyu Hong, Seok-Soo Byun, Gheeyoung Choe, Sang Eun Lee From the Department of Urology, Inje University Sanggye Paik Hospital, Seoul, Departments of Urology and Pathology, Seoul National University Bundang Hospital, Seongnam, Department of Urology, Seoul National University Hospital, KEPCO Medical Foundation Hanil General Hospital, Seoul, Korea